A 62-year-old woman with type 2 diabetes mellitus and essential hypertension presents for … — USMLE Step 3

A $62$ -year-old woman with type 2 diabetes mellitus and essential hypertension presents for a routine follow-up. She is currently asymptomatic. Her daily medications include metformin and lisinopril. Her most recent hemoglobin A1c is $7.4\%$ , and her serum creatinine is $1.2$ mg/dL. During the visit, she shows the physician a magazine advertisement for a newly approved diabetes medication, *Renagliflozin*. The advertisement features a prominent headline: "Proven to reduce major diabetic complications by 30%!" The patient asks if she should start this medication specifically to reduce her risk of having a heart attack.

The physician reviews the fine print of the advertisement, which includes a data table from the drug's pivotal randomized controlled trial comparing *Renagliflozin* to placebo over a 4-year period.

Outcome Component	Renagliflozin ( $n=2000$ )	Placebo ( $n=2000$ )	Hazard Ratio ( $95\%$ CI)	$p$ -value
Primary Composite Endpoint*	$10.5\%$	$15.0\%$	$0.70$ ( $0.61 - 0.80$ )	$< 0.001$
Cardiovascular Death	$2.2\%$	$2.4\%$	$0.94$ ( $0.80 - 1.10$ )	$0.65$
Non-fatal Myocardial Infarction	$2.5\%$	$2.6\%$	$0.96$ ( $0.82 - 1.12$ )	$0.72$
Non-fatal Stroke	$1.8\%$	$1.9\%$	$0.92$ ( $0.75 - 1.15$ )	$0.68$
Doubling of Serum Creatinine	$4.0\%$	$8.1\%$	$0.49$ ( $0.41 - 0.58$ )	$< 0.001$

*\*The primary composite endpoint is defined as the occurrence of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or doubling of serum creatinine.*

Based on the provided literature, which of the following is the most appropriate response to the patient's inquiry about preventing a heart attack?

The drug significantly lowers the risk of the primary composite outcome, but this benefit is driven by a reduction in renal disease progression rather than a reduction in myocardial infarctions.Answer
B
The trial data demonstrates that initiating this drug will provide a 30% absolute risk reduction in overall diabetic complications.
C
The narrow confidence interval of the primary composite endpoint confirms that the drug provides a statistically significant reduction in cardiovascular death.
D
The drug should be withheld because its co-administration with lisinopril leads to a severe pharmacokinetic interaction that increases the risk of adverse events.
E
The drug is contraindicated because a serum creatinine level of 1.2 mg/dL represents a critical laboratory abnormality that precludes safe clearance of the medication.

Answer

The drug significantly lowers the risk of the primary composite outcome, but this benefit is driven by a reduction in renal disease progression rather than a reduction in myocardial infarctions.

In medical literature, a composite endpoint combines multiple outcomes into a single metric to increase statistical power. However, interpreting a positive composite endpoint requires examining its individual components. In this trial, while the primary composite endpoint is statistically significant (

p < 0.001

), the specific endpoints for cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke all have confidence intervals crossing

1.0

and

p

-values

> 0.05

. This indicates no significant cardiovascular benefit. The entire

30\%

relative risk reduction claimed by the advertisement is driven by a single component: the progression of microalbuminuria/doubling of serum creatinine (HR

0.49

p < 0.001

). Therefore, it is most appropriate to counsel the patient that the drug protects renal function but has not been proven to prevent heart attacks.

Step-by-Step Solution

Analyze the patient's specific question.

The patient wants to know if the medication will reduce her risk of having a heart attack (myocardial infarction).

Directs focus to the relevant specific data in the trial table rather than the overall marketing claim.

Evaluate the primary composite endpoint in the provided table.

The composite endpoint shows a significant reduction: Hazard Ratio

0.70

95\%

CI (

0.61 - 0.80

p < 0.001

This confirms the advertisement's claim of a

30\%

Relative Risk Reduction (

1 - 0.70 = 0.30

) for the combined outcome.

Examine the individual components of the composite endpoint, specifically myocardial infarction.

The non-fatal myocardial infarction component has a Hazard Ratio of

0.96

with a

95\%

CI of (

0.82 - 1.12

) and

p = 0.72

Because the confidence interval crosses

1.0

and the

p

-value is greater than

0.05

, there is no statistically significant reduction in heart attacks.

Identify which component is driving the significance of the composite endpoint.

The 'Doubling of Serum Creatinine' endpoint has an HR of

0.49

(

95\%

0.41 - 0.58

p < 0.001

The large effect size and statistical significance of this single renal surrogate marker are masking the lack of efficacy in the cardiovascular endpoints when pooled together.

Key Concept

Interpretation of Composite Endpoints

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic